Methods for Modulating Tumor Growth and Metastasis

Abstract

Methods and pharmaceutical compositions for modulating tumor growth or metastasis are provided.

1 - 60 . (canceled) 
   
   
       61 . A method for modulating tumor growth or metastasis in an animal in need thereof, comprising sequential or simultaneous administration of a taxane and a combretastatin compound in amounts effective therefore. 
   
   
       62 . The method of  claim 61 , wherein said taxane is selected from the group consisting of paclitaxel and docetaxel. 
   
   
       63 . The method of  claim 61 , wherein said combretastatin compound is a combretastatin A-4 compound. 
   
   
       64 . The method of  claim 63 , wherein said combretastatin A-4 compound is combretastatin A-4 phosphate. 
   
   
       65 . The method of  claim 63 , wherein said combretastatin A-4 phosphate is administered at least 3 hours prior to the taxane. 
   
   
       66 . The method of  claim 61 , wherein said combretastatin compound is a combretastatin A-1 compound. 
   
   
       67 . The method as claimed in  claim 66 , wherein said combretastatin A-1 compound is combretastatin A-1 phosphate. 
   
   
       68 . The method as claimed in  claim 66 , wherein said combretastatin A-1 compound is combretastatin A-1 phosphate and said taxane is paclitaxel. 
   
   
       69 . The method as claimed in  claim 68 , wherein said combretastatin A-1 phosphate is administered at least 3 hours prior to paclitaxel. 
   
   
       70 . A method for modulating tumor growth or metastasis in an animal in need thereof, comprising administration of a combretastatin compound and a taxane, in amounts effective therefor, wherein said combretastatin compound is administered at a time relative to administration of said taxane sufficient to modulate blood flow to said tumor to provide a time-dependent effective tumor concentration of said taxane. 
   
   
       71 . A pharmaceutical composition for modulating tumor growth or metastasis in an animal in need thereof, comprising a taxane and a combretastatin compound, in amounts effective therefore in a pharmaceutically acceptable carrier. 
   
   
       72 . The pharmaceutical composition as claimed in  claim 71 , wherein said taxane is paclitaxel or docetaxel. 
   
   
       73 . The pharmaceutical composition of  claim 71 , wherein said combretastatin compound is a combretastatin A-4 compound. 
   
   
       74 . The pharmaceutical composition of  claim 71 , wherein said combretastatin compound is a combretastatin A-1 compound.